Literature DB >> 23893409

Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.

Neal R Rasmussen1, Tricia M Wright, Samira A Brooks, Kathryn E Hacker, Zufan Debebe, Adam B Sendor, Matthew P Walker, Michael Ben Major, Jennifer Green, Geoffrey M Wahl, W Kimryn Rathmell.   

Abstract

Expression of the receptor tyrosine kinase-like orphan receptor 2 (Ror2) has been identified in an increasing array of tumor types and is known to play a role as an important mediator of Wnt signaling cascades. In this study, we aimed to clarify Ror2 interactions with the Wnt pathways within the context of renal cell carcinoma (RCC). An examination of Ror2 expression in primary human RCC tumors showed a significant correlation with several Wnt signaling genes, including the classical feedback target gene Axin2. We provide evidence that Ror2 expression results in a partially activated state for canonical Wnt signaling through an increased signaling pool of β-catenin, leading to an enhancement of downstream target genes following Wnt3a stimulation in both renal and renal carcinoma-derived cells. Additionally, inhibition of low-density lipoprotein receptor-related protein 6 (LRP6) with either siRNA or dickkopf decreased the response to Wnt3a stimulation, but no change was seen in the increased β-catenin pool associated with Ror2 expression, suggesting that LRP6 cofactor recruitment is necessary for a Wnt3a-induced signal but that it does not participate in the Ror2 effect on β-catenin signaling. These results highlight a new role for Ror2 in conveying a tonic signal to stabilize soluble β-catenin and create a poised state of enhanced responsiveness to Wnt3a exogenous signals in RCC.

Entities:  

Keywords:  Cancer; RCC; Receptor Tyrosine Kinase; Renal Cell Carcinoma; Ror2; Signaling; Wnt Signaling; Wnt3a; β-Catenin

Mesh:

Substances:

Year:  2013        PMID: 23893409      PMCID: PMC3764835          DOI: 10.1074/jbc.M113.466086

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development.

Authors:  R Al-Shawi; S V Ashton; C Underwood; J P Simons
Journal:  Dev Genes Evol       Date:  2001-04       Impact factor: 0.900

2.  Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity.

Authors:  Masaki Kobayashi; Yasuyuki Shibuya; Junichiro Takeuchi; Maho Murata; Hiroaki Suzuki; Satoshi Yokoo; Masahiro Umeda; Yasuhiro Minami; Takahide Komori
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03

3.  The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.

Authors:  Benedetta Peruzzi; Gagani Athauda; Donald P Bottaro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

4.  The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells.

Authors:  Julia Billiard; Deana S Way; Laura M Seestaller-Wehr; Robert A Moran; Annamarie Mangine; Peter V N Bodine
Journal:  Mol Endocrinol       Date:  2004-09-23

5.  Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL.

Authors:  Vipul C Chitalia; Rebecca L Foy; Markus M Bachschmid; Liling Zeng; Maria V Panchenko; Mina I Zhou; Ajit Bharti; David C Seldin; Stewart H Lecker; Isabel Dominguez; Herbert T Cohen
Journal:  Nat Cell Biol       Date:  2008-09-21       Impact factor: 28.824

6.  Wnt-5A/Ror2 regulate expression of XPAPC through an alternative noncanonical signaling pathway.

Authors:  Alexandra Schambony; Doris Wedlich
Journal:  Dev Cell       Date:  2007-05       Impact factor: 12.270

7.  The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation.

Authors:  Stephane Angers; Chris J Thorpe; Travis L Biechele; Seth J Goldenberg; Ning Zheng; Michael J MacCoss; Randall T Moon
Journal:  Nat Cell Biol       Date:  2006-03-19       Impact factor: 28.824

8.  Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.

Authors:  Amanda J Mikels; Roel Nusse
Journal:  PLoS Biol       Date:  2006-04-04       Impact factor: 8.029

9.  WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/β-catenin pathway.

Authors:  Ren-Jun Hsu; Jar-Yi Ho; Tai-Lung Cha; Dah-Shyong Yu; Chieh-Lin Wu; Wei-Ping Huang; Pauling Chu; Ying-Hsin Chen; Jiann-Torng Chen; Cheng-Ping Yu
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

10.  Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2.

Authors:  Changgong Li; Hongyan Chen; Lingyan Hu; Yiming Xing; Tomoyo Sasaki; Maria F Villosis; John Li; Michiru Nishita; Yasuhiro Minami; Parviz Minoo
Journal:  BMC Mol Biol       Date:  2008-01-23       Impact factor: 2.946

View more
  16 in total

1.  Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Authors:  Sean S Q Ma; Claire E Henry; Estelle Llamosas; Rupert Higgins; Benjamin Daniels; Luke B Hesson; Nicholas J Hawkins; Robyn L Ward; Caroline E Ford
Journal:  Virchows Arch       Date:  2016-09-08       Impact factor: 4.064

2.  Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer.

Authors:  Bo Sun; Xiufeng Ye; Li Lin; Mei Shen; Taotao Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Upregulation of non-canonical Wnt ligands and oxidative glucose metabolism in NASH induced by methionine-choline deficient diet.

Authors:  Lixin Zhu; Susan S Baker; Abdul Shahein; Shelly Choudhury; Wensheng Liu; Tavleen Bhatia; Robert D Baker; Techung Lee
Journal:  Trends Cell Mol Biol       Date:  2018

4.  Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

Authors:  C Henry; A Quadir; N J Hawkins; E Jary; E Llamosas; D Kumar; B Daniels; R L Ward; C E Ford
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-11       Impact factor: 4.553

Review 5.  Ror2 as a therapeutic target in cancer.

Authors:  Zufan Debebe; W Kimryn Rathmell
Journal:  Pharmacol Ther       Date:  2015-01-19       Impact factor: 13.400

6.  Bioinformatics-Based Identification of MicroRNA-Regulated and Rheumatoid Arthritis-Associated Genes.

Authors:  Yi-Jiang Song; Guiling Li; Jian-Hua He; Yao Guo; Li Yang
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

7.  Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.

Authors:  Neal R Rasmussen; Zufan Debebe; Tricia M Wright; Samira A Brooks; Adam B Sendor; A Rose Brannon; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; Eric M Wallen; Catherine Simpson; Jacqueline L Norris; William P Janzen; W Kimryn Rathmell
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

8.  Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Authors:  Claire Henry; Estelle Llamosas; Alexandra Knipprath-Meszaros; Andreas Schoetzau; Ellen Obermann; Maya Fuenfschilling; Rosemarie Caduff; Daniel Fink; Neville Hacker; Robyn Ward; Viola Heinzelmann-Schwarz; Caroline Ford
Journal:  Oncotarget       Date:  2015-11-24

9.  ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.

Authors:  Sean S Q Ma; Sameer Srivastava; Estelle Llamosas; Nicholas J Hawkins; Luke B Hesson; Robyn L Ward; Caroline E Ford
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

10.  Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer.

Authors:  Chenlin Lu; Xudong Wang; Huijun Zhu; Jian Feng; Songshi Ni; Jianfei Huang
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.